Join us on October 20, 2020 as we launch a new AACE.
AACE is a dynamic organization that is leading the way in the endocrine community with clinical knowledge and experience.
Join us on October 20, 2020 as we launch a new AACE.
AACE is a dynamic organization that is leading the way in the endocrine community with clinical knowledge and experience.
September 16, 2020
An update on outcomes of the virtual Annual Business Meeting that occurred on September 11, 2020.
Anyone with commercial insurance, and those without insurance at all, can continue filling their monthly prescription of Lilly insulins for $35 through this program.
The U.S. Food and Drug Administration (FDA) approved two additional doses of Eli Lilly and Company's (NYSE: LLY) Trulicity® (dulaglutide). The approval expands the label of once-weekly Trulicity to include 3.0 mg and 4.5 mg doses based on data from AWARD-11. The phase 3 trial showed the additional doses led to further benefits in A1C and body weight reduction when compared to Trulicity 1.5 mg in people with type 2 diabetes.
September 8, 2020
Read more about thyroid eye disease, including recent research and case studies from Endocrine Practice and AACE Clinical Case Reports.
Drs. Leslie Eldeiry, Scott Isaacs, and Matthew Levine provide an important AACE member update on behalf of the Board of Directors on two upcoming changes regarding our brand and community. These will be further discussed at the Annual Business Meeting on September 11, 2020.
The Annual Business Meeting of the AACE membership will be held via a ZOOM Virtual Conference Call on Friday, September 11, 2020, from 4:00 pm – 5:00 pm EST. Registration is required.
AbbVie has launched a new SYNTHROID DELIVERS PROGRAM, a direct-to-patient pharmacy program that offers patients a cash-pay option to receive Synthroid consistently and conveniently.
Here is a round-up of four different online, ondemand courses you can take that will walk you through the guidelines and help you apply them to your practice.
August 18, 2020
The FACE application period is open until November 2, 2020. Applications will only be accepted online, and eligible candidates must meet the criteria set forth by the FACE Application Committee.
A new policy statement from AACE including background and recommendations for access to diabetes medication and technology
The COVID-19 public health emergency declaration has officially been extended for another 90 days by Health and Human Services. Secretary Alex Azar endorsed the renewal on July 23, just before it was set to expire July 25.
President Trump signed four executive orders aimed at lowering the prices Americans pay for prescription drugs, including insulin.
July 8, 2020
To heighten awareness of hypoglycemia, AACE is excited to announce 'The Lowdown on Low Blood Sugar' campaign.
July 24, 2020
Keep your whole endocrine care team up to date on glucose monitoring and other topics – for FREE!
In the era of COVID-19, many in-office visits have been able to convert to virtual appointments. Many ask, how is a telemedicine visit different, and how can I get the most from it?
May 12, 2020
We’ve partnered with Beyond Type 1, a nonprofit organization aiming to unite the global diabetes community and provide solutions to improve lives, to develop Armed For Diabetes,* a campaign to educate veterans on how they can gain access to the latest diabetes management tools.
May 6, 2020
Dr. Sandra Weber, AACE President 2019-2020, and Dr. Howard Lando, AACE President 2020-2021, deliver addresses to the American Association of Clinical Endocrinologists (AACE) community. Introduction by Paul Markowski, AACE CEO.
Organizations responding to "paucity of data” to provide clear guidance for healthcare professionals treating millions of osteoporosis patients.
April 29, 2020
Though we sadly cannot celebrate in person at our annual congress, we are happy to congratulate our 2020 Awards, MACE and FACE recipients here on AACE.com. All recipients will be honored during the AACE 30th Annual Scientific & Clinical Congress in 2021.
View a special section highlighting the 2020 AACE/ACE Awards winners and read their bios.
AACE Frontiers in Science
April 29, 2020
We are pleased to report to you the results of the AACE 2020 elections. Dr. Daniel L. Hurley, Chair of the Nominating Committee, thanks the members of the Nominating Committee for their time and effort evaluating a number of excellent candidates for Officer positions and the Board of Directors and for developing a strong slate of candidates for the 2020 election.
AACE members Gauri Behari, MD, Karyne Vinales, MD, and Ricardo Correa MD, Es.D, share their experience with telemedicine tools both before and after the COVID-19 health crisis.
April 20, 2020
We continue to think of you during this unprecedented season. While over the last several weeks you have received many helpful pieces of guidance, research, and news updates - today we simply wish to remind you that our priority remains to be you: our members. You are the heart of AACE, and you are our foremost thought that guides anything and everything we do.
Initial research suggests that people with cardiometabolic disease are at increased risk of experiencing complications from infection with COVID-19 and may be more susceptible to contracting the virus.
There is currently no reason to believe that most people with thyroid disease are at increased risk to contract this novel coronavirus or to experience complications. Nevertheless, if thyroid medications are not taken as prescribed, uncontrolled thyroid disease may increase a person’s risk for viral infection and complications.
April 10, 2020
It is with great sadness that I share the news of Dr. Alan Garber’s passing yesterday on April 9, 2020. Dr. Garber was a Charter Member of AACE, as well as a Past President of both AACE and ACE.
A new $35 co-pay is available through the Lilly Insulin Value Program in response to the COVID-19 crisis in the U.S.
With the novel COVID-19 virus continuing to spread, it is crucial to adhere to the advice from experts and the Centers for Disease Control and Prevention (CDC) to help reduce risk of infection for individuals and the population at large. This is particularly important for people with adrenal insufficiency and people with uncontrolled Cushing’s Syndrome.
At this time, the leading pharmaceutical manufacturers are reporting that COVID-19 is NOT having an impact on their manufacturing and distribution capabilities for insulin and other related supplies.
The U.S. Food and Drug Administration has updated the Nutrition Facts label.
August 18, 2020 (Latest Update)
AACE is closely monitoring developments regarding COVID-19 and working with partner medical societies to provide information and resources to our members. Click to view COVID-19 resources, including more about navigating telehealth services.
AACE releases update on COVID-19 and the risks and recommended preparations for patients with diabetes.
In an effort to limit the spread of the coronavirus, the Trump Administration announced today that it is expanding Medicare telehealth coverage so that beneficiaries can receive healthcare services without having to travel to their physician's office.
AACE invites nominations and applications for two, separate positions:
1) Editor-in-Chief of Endocrine Practice (EP)
2) Editor-in-Chief of AACE Clinical Case Reports (ACCR)
Endocrine Practice (EP) publishes original articles, review articles, commentaries, editorials and visual vignettes. The primary mission of Endocrine Practice is to enhance the health care of patients with endocrine diseases through continuing education of practicing endocrinologists.
As the coronavirus (COVID-19) continues to spread in the United States, it is important for everyone to take the necessary precautions to help prevent infection and spread of the virus. While it is difficult to assess the unique implications of COVID-19 in people with diabetes (type 1, type 2, or gestational) at this time, diabetes and other chronic medical conditions can make patients more vulnerable to infections, leading to serious consequences. In addition, uncontrolled diabetes with hyperglycemia is known to impair immune function.
AACE is closely monitoring the information being shared about the virus and will take the precautions needed to promote the health and safety of our staff and members attending the EMBRAACE annual meeting.
Coinciding with World Obesity Day, AACE has joined over 100 medical and scientific organizations across the world in pledging our support for a consensus statement that recognizes unscientific public narratives of obesity as a major cause of weight stigma and calls for strong policies and legislation to prevent weight-based discrimination.
May 29, 2020 (Latest Update)
AACE is excited to share all the benefits of this improved system with you. Watch a video walkthrough and read in-depth instructions on accessing the AACE Learning Center and its helpful features.
February 14, 2020
Due to signals in safety clinical trials showing possible increased risk of cancer, The U.S. Food and Drug Administration (FDA) requested that the manufacturer of Belviq, Belviq XR (lorcaserin) voluntarily withdraw the weight-loss drug from the U.S. market.
The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death. Click to read which models are affected.
February 3, 2020
The AACE diabetes algorithm is a comprehensive management algorithm that covers lifestyle, obesity, prediabetes, lipids, hypertension and glucose management strategies.
The former American Association of Diabetes Educators is now the Association of Diabetes Care & Education Specialists (ADCES). The rebranding reflects the association’s shift from referencing the specialty title as “diabetes educator” to the more comprehensive “diabetes care and education specialist.”
January 10, 2020
In compliance with the AACE Bylaws, the AACE Nominating Committee is pleased to notify the membership of the selection of the following preliminary slate of candidates for election to Officer positions for a one-year (1) term.
November 4, 2019
AACE has released updated guidelines for the perioperative nutrition, metabolic and nonsurgical support of patients undergoing bariatric procedures.
The Physician Fee Schedule for CY 2021 includes an an overall 16 percent increase in E/M codes for Endocrinology – the most of any specialty. A record number of AACE members responded to an AACE “Action Alert” and sent comments to CMS in September in support of the higher valuations – thank you! Unfortunately CMS did NOT place FNA codes on the “potentially mis-valued” list, closing the door to a process to increase these codes, which were substantially reduced this year.
October 15, 2019
As of January 1, 2019, Medicare will pay separately for a newly defined type of physicians' service termed as, “Brief communication technology-based service, e.g. virtual check-in…" The HCPCs code is G2012 and is defined as,
October 8, 2019
October 18, 2019 | AACE joins the International Life Sciences Institute in hosting the free webinar, "Tools and Tactics for Reducing Added Sugars Intake: Guidance for Practitioners with a Focus on Low-Calorie Sweetener Safety and Appropriate Use."
The Medullary Thyroid Carcinoma (MTC) Registry Consortium* is partnering with the American Thyroid Association® (ATA) to create a registry (list) of all new cases of MTC diagnosed in the United States over the next 10-15 years (the MTC Registry).
September 6, 2019
Pharmaceutical company Takeda has announced the recall of the its parathyroid hormone for injection, NATPRA.
August 12, 2019
The Government Accountability Office (GAO) has released a new study on prescription drug use to treat obesity.
August 8, 2019
The CDC recently launched in collaboration with Google Health, a prediabetes quiz that will pop up when end users search for certain medical information using their Google browser to bring more public awareness about prediabetes.
Medicare imposed substantial cuts in reimbursements for the new and revised fine needle aspiration codes for 2019. AACE, together with the Endocrine Society and American Thyroid Association, advocated for you with letters to Centers for Medicare and Medicaid Services (CMS) and Congress opposing these cuts. We secured a win with the release of the proposed physician pay rule issued July 29.
Medscape reports the nasal powder, used in the treatment of severe hypoglycemia for patients aged 4 years or older, is the first licensed glucagon product that is not delivered by injection and that does not require a multistep mixing process.
The FACE application period is from Monday, August 12, 2019, 8:00 am ET to Friday, November 01, 2019, 5:00 pm, ET. FACE Applications for 2020 will only be accepted through an online process.
Prasad, M. et al. Triglyceride and Triglyceride/HDL (High Density Lipoprotein) Ratio Predict Major Adverse Cardiovascular Outcomes in Women With Non-Obstructive Coronary Artery Disease. J Am Heart Assoc. 2019;8:e009442. DOI: 10.1161/JAHA.118.009442.)
Chait, A. and Eckel, R. The Chylomicronemia Syndrome Is Most Often Multifactorial. Ann Intern Med. 2019;170:626-634. doi:10.7326/M19-0203
Arnett DK, Blumenthal RS, Albert MA et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation 2019:Cir0000000000000678
Hawley CE, et al. Statins for Primary Prevention in Those Aged 70 Years and Older: A Critical Review of Recent Cholesterol Guidelines. Drugs Aging 2019
Kim DW, et al. Association between statin treatment and new-onset diabetes mellitus: a population based case-control study. Diabetology & metabolic syndrome 2019; 11:30
Schleyer T, Hui S, Wang J, et al. Quantifying unmet need in statin-treated hyperlipidemia patients and the potential benefit of further LDL-C reduction through an EHR-based retrospective cohort study. J Manag Care Spec Pharm. 2019;25(5):544-554.
Presenting PrescriptionHelp.aace.com – A directory of prescription affordability programs and resources for your endocrine patients to help them acquire the medications they need at reduced out-of-pocket costs.
June 28, 2019
In the systematic review and meta-analysis of more than 4,000 patients with adenomas published in the Annals of Internal Medicine (Elhassan et al), authors reported that patients with mild autonomous cortisol secretion or nonfunctioning adrenal adenomas very rarely develop overt hormonal excess (<0.1%). In addition, adenoma growth >1cm occurred only in 2.5% of patients and no patient developed an adrenal malignancy at follow up.
The U.S. Food and Drug Administration is warning patients and health care providers that certain Medtronic MiniMed insulin pumps are being recalled due to potential cybersecurity risks.
When it comes to optimal bone health and fracture prevention, there is scant evidence for recommending supplementation with vitamins and minerals other than calcium and vitamin D, according to AACE member Daniel L. Hurley, MD, FACE, who spoke at the AACE 28th Annual Scientific & Clinical Congress.
This year, at the 28th Annual Scientific & Clinical Congress, AACE made changes to the traditional lecture format and pushed for casual presentations, allowing more in-depth and interactive conversations. Read about the change from a member's perspective in this editorial by Archana Sadhu, MD, FACE, longtime Los Angeles resident.
Findings presented at the AACE 28th Annual Scientific & Clinical Congress showed that seeking hospital care for diabetic ketoacidosis during the weekend as opposed to during the week may increase mortality risk.
April 25, 2019
Type 2 diabetes (T2D) is associated with increased risk for fractures in the short term but not in the long term, according to study results presented at the AACE 28th Annual Scientific & Clinical Congress.
Treatment with linagliptin in patients with type 2 diabetes (T2D) and cardiovascular and/or kidney disease had no impact on risk for cardiovascular or kidney events or hospitalization for heart failure, according to results of the CARMELINA study (Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus) presented at the AACE 28th Annual Scientific & Clinic
Abaloparatide followed by alendronate treatment may improve bone mineral density (BMD) in women with postmenopausal osteoporosis and type 2 diabetes (T2D), according to study results presented at the AACE 28th Annual Scientific & Clinical Congress.
The use of an insulin pump to deliver continuous pulsatile cortisol may be a viable treatment option in patients with severe adrenal insufficiency who are unresponsive to oral corticosteroids, according to study results presented at the AACE 28th Annual Scientific & Clinical Congress.
Biochemical markers and clinical signs and symptoms of endogenous Cushing syndrome improved after 6 months of levoketoconazole therapy, according to phase 3 study results presented at the AACE 28th Annual Scientific & Clinical Congress.
Significantly more euthyroid patients with thyroid disease suffer from anxiety compared with depression, regardless of whether they have Hashimoto thyroiditis autoimmunity, according to research results presented at the AACE 28th Annual Scientific & Clinical Congress.
A weighted cardiometabolic disease staging risk score can be used to quantify race- and sex-specific type 2 diabetes risk in a large, diverse population, according to study results presented at the AACE 28th Annual Scientific & Clinical Congress.
Hypothyroidism is a risk factor for increased length of hospital stay and mortality in patients with congestive heart failure (CHF), according to study results presented at the AACE 28th Annual Scientific & Clinical Congress.
Teprotumumab effectively reduces proptosis in patients with active thyroid eye disease, according to phase 3 confirmatory trial data presented at the AACE 28th Annual Scientific & Clinical Congress.
For indeterminate thyroid nodules following fine needle aspiration, evidence of thick post-microcystic reflection on ultrasound was found to be associated with malignant nodules, according to study results presented at the AACE 28th Annual Scientific & Clinical Congress.
Lower income and education levels may negatively affect the experience and expectations of patients who are obese who receive care for weight management, according to study results presented at the AACE 28th Annual Scientific & Clinical Congress.
The cardiovascular and renal effects of treatment with canagliflozin in patients with type 2 diabetes are more prominent in patients not taking metformin compared with patients treated with canagliflozin as an add-on to metformin, according to data from the CANVAS (CANagliflozin cardioVascular Assessment Study) Program presented at the AACE 28th Annual Scientific & Clinical Congress.
May 10, 2019
Endocrine Today has compiled a list of the top five news stories posted from the American Association of Clinical Endocrinologists Scientific & Clinical Congress, held April 24-28, 2019, in Los Angeles.
April 28, 2019
Distinctive serum steroid profiles might emerge in patients with adrenal tumors and Cushing's syndrome, according to research reported by Shobana Athimulam, MBBS, of the Mayo Clinic in Rochester, Minnesota, and colleagues, at the AACE 28th Annual Scientific & Clinical Congress.
April 28, 2019
The ThyroSeq v3 Genomic Classifier was able to effectively classify thyroid nodules with samples collected through fine needle aspiration (FNA), according to research reported by Lindsey Tolino, MBA, of the University of Pittsburgh Medical Center in Pennsylvania, and colleagues, at the AACE 28th Annual Scientific & Clinical Congress.
April 28, 2019
The investigational agent teprotumumab was effective for reducing proptosis associated with thyroid eye disease, according to late-breaking phase III data presented by Raymond Douglas, MD, PhD, of Cedars Sinai Medical Center in Los Angeles, and colleagues, at the AACE 28th Annual Scientific & Clinical Congress.
April 29, 2019
The investigational agent relacorilant significantly improved excess cortisol in patients with endogenous hypercortisolism, researchers reported at the AACE 28th Annual Scientific & Clinical Congress.
Among patients on hemodialysis, trabecular bone score was helpful in predicting fracture risk, researchers reported during an oral presentation of the findings at AACE’s 28th Annual Scientific & Clinical Congress.
AACE Member Roy Taylor, MD, discussed the pathogenesis of hepatic insulin resistance in people with type 2 diabetes in an interview at AACE’s 28th Annual Scientific & Clinical Congress.
AACE Member Felicia Cosman, MD, professor of medicine at Columbia University, New York, discussed the current state of osteoporosis treatment in an interview at AACE’s 28th Annual Scientific & Clinical Congress.
June 10, 2019
Lewis E. Braverman, MD, MACE, 89, passed away peacefully on Monday, June 10, 2019. He leaves his wife Mimi Braverman; his sons, William Braverman and Daniel Braverman; and his five grandchildren.
In a recent interview with the AACE2019News.com, Yulino Castillo Núñez, MD, recipient of the 2019 AACE International Clinician Award, discussed some of the greatest influences on his career in endocrinology.
April 21, 2019
Kevin Pho, MD, is a board-certified internal medicine physician and founder of KevinMD, social media’s leading physician voice. He has been named the web’s top social media influencer in health care and medicine. Dr. Pho is coming to AACE to deliver the keynote address “Social Media and the Physician” on Saturday, April 27. AACE2019News.com recently had the opportunity to ask Dr. Pho a few questions about his presentation, social media and why endocrinologists should get on the social media train.
Bhatt DL, Steg G, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11-22.https://www.nejm.org/doi/full/10.1056/NEJMoa1812792
Treatment of hypercholesterolemia with statins results in significant reductions in cardiovascular risk; however, individuals with well-controlled low-density lipoprotein cholesterol (LDL-C) levels, but persistent high triglycerides (TG), remain at increased risk.
Shin J, Chung JW, Jang HS et al. Achieved low-density lipoprotein cholesterol level and stroke risk: A meta-analysis of 23 randomised trials. Eur J Prev Cardiol 2019:2047487319830503.http://www.ncbi.nlm.nih.gov/pubmed/?term=30782002
Fogacci F, Banach M, Mikhailidis DP et al. Safety of Red Yeast Rice Supplementation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pharmacol Res. 2019; 143:1-16.http://www.ncbi.nlm.nih.gov/pubmed/?term=30844537
Ference BA, Ray KK, Catapano AL, et al. Mendelian Randomization Study of ACLY and Cardiovascular Disease.
Ray KK, Bays HE, Catapano AL, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019;380:1022-1032.https://www.nejm.org/doi/full/10.1056/NEJMoa1803917
An estimated 30.3 million Americans have type 2 diabetes (T2D), a complex, progressive disease that requires intensified treatment over time.1-3 The complexity of T2D management, coupled with the need to tailor treatment recommendations to individual patients, presents an ongoing clinical challenge. The number and variety of treatment options available for T2D has increased dramatically in the last 15 years, with several new drug classes emerging as safe and effective.2,4,5
Jan 8, 2019
A preliminary slate of candidates for the election of Officer positions for a one-year (1) term, five (5) open positions on the Board of Directors for election to a three-year (3) term (2019-2022) and one (1) open position on the Board of Directors for a one-year (1) term (2019-2020) to fill the unexpired term of Dr. Sethu Reddy, who was elected Secretary in 2018, was sent to the membership via email/fax on December 28.